Better Therapeutics, Inc. · OTC:BTTX
Better Therapeutics — Technical Presentation (July 2022)
41 slides from Better Therapeutics's technical presentation, Jul 28, 2022
Slide 1: BT-001 Pivotal Clinical Trial Results
Exhibit 99.2 JULY 28, 2022 BT-001 Pivotal Clinical Trial Results
Slide 2: Disclaimer
Disclaimer This presentation (“Presentation”) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTX” or the Company“) nor any of its respective affiliates nor any of its or their control persons, off
Slide 3: Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases
Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases
Slide 4: BT-001 Pivotal Trial: key results summary
Primary Endpoint assessed at 90 days showed significant decrease in A1c as compared to control group receiving standard of care (p<0.0001) Secondary Endpoint assessed at 180 days demonstrated sustained and BT-001 Pivotal Trial: improved response (p=0.01) Half of patients in BT arm achieved clinicall
Slide 5: Unique Benefits of Digital Therapeutics Instead of Drugs
Opportunity to address healthcare inequities and access– Digital therapeutics can reach patients where they are and connect them to the best care despite the many barriers patients experience Real-time insights into use and efficacy enables continuous improvement promising the potential for increasi
Slide 6: Next Generation Therapeutics: The Better Therapeutics Approach
Next Generation Therapeutics: The Better Therapeutics Approach Developing Digital Therapeutics that are cleared by the FDA for a specific indication and have labeled claims. If cleared, patients obtain access through a physician prescription that is reimbursed via health insurance Initially focused
Slide 7: BT-001 Pivotal Trial Results
BT-001 Pivotal Trial Results BT-001 demonstrated sustained and improved response at 180 days, with absolute A1c reduction advancing from 0.3% to 0.4%, highlighting potential for long-term Baseline A1c D90 A1c D180 A1c improvements 0.2 1.5x more SOC patients • Both primary (A1c between group delta -0
Slide 8: BT-001 Pivotal Trial Designed for FDA De Novo Authorization
Nationally representative, diverse patient population Investigators mirror real-world prescribers BT-001 Pivotal Robust study design employed to minimize bias and set high comparison bar: Trial designed • Control arm is Standard of Care (i.e. gold standard care), primarily for not just treatment as
Slide 9: Nationally representative, diverse patient population recruited
Nationally representative, diverse patient population recruited Patient population recruited from 6 States, includes groups underrepresented in clinical trials, with historically poor access to care Standard of Care BT-001 Parameter / Category Statistic (n=343) (n=325) Age (yrs) Mean 58.1 58.0 % Fem
Slide 10: Participants had long-standing T2 diabetes, high cardiovascular risk, extensive medication use
Participants had long-standing T2 diabetes, high cardiovascular risk, multiple comorbidities and extensive medication use Standard of Care BT-001 Parameter / Category Statistic (n=343) (n=326) 2 BMI (kg/m ) Mean 34.7 34.6 Baseline HbA1c (%) Mean 8.1% 8.2% Years Since Diagnosis Mean 10.9 11.0 % on 2
Slide 11: Baseline diabetes medications reveal robust background therapy
General Diabetes Population Medication Class SOC BT-001 1 (2018) All 82.7% 96.5% 96.0% Baseline diabetes Metformin 59.5% 79.9% 80.1% medications reveal Sulfonylureas 24.4% 34.4% 36.2% robust background SGLT2 inhibitors < 7.1% 24.8% 21.8% therapy compared GLP-1 analogues < 7.1% 24.8% 19.0% with gener
Slide 12: BT-001 produced clinically meaningful and sustained reduction in A1c
BT-001 produced clinically meaningful and sustained reduction in A1c Baseline A1c D90 A1c D180 A1c 0.2 0.1 0 BT-001 -0.1 Primary EndPoint -0.2 Secondary EndPoint -0.3 -0.4 Intent-to-Treat Analysis 12 % Mean Change in A1c
Slide 13: BT-001 reduced A1c despite more medication added in control group
BT-001 reduced A1c despite on-study addition of more diabetes medication in the Standard of Care control group Baseline A1c D90 A1c D180 A1c 0.2 1.5x more SOC patients 0.1 increased meds prior to day 180* SOC 0 BT-001 Primary EndPoint 0.4% Delta, -0.1 p < 0.0001 Secondary EndPoint -0.2 0.3% Delta, p
Slide 14: Trending average change in fasting blood glucose
Trending average change in fasting blood glucose shows gradual and steady improvements, with no clear peak 14
Slide 15: Trends in fasting blood glucose in different therapies
Trends in fasting blood glucose in different therapies 0 -4 -8 -12 -16 -20 Baseline W4 W8 W12 W16 W20 W24 BT-001 Ferrannini E et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 tr
Slide 16: Cardiovascular Outcome Trials show lower relative A1c reduction
Cardiovascular Outcome Trials (CVOTs) show lower relative A1c reduction compared with new drug pivotal for same drug New Drug Approval Pivotal 0.8% Trulicity (GLP-1 RA Inj.) 1% CV Outcome Trial New Drug Approval Pivotal 0.8% Jardiance (SGLT2) 1% CV Outcome Trial New Drug Approval Pivotal 0.8% Januvi
Slide 17: Trial design may influence A1c reduction observed
Trial design may influence A1c reduction observed. BT-001 pivotal trial design is more similar to diabetes cardiovascular outcome trials Trial Characteristic New Drug Pivotal CV Outcome Trial BT-001 Pivotal Poorly Controlled Diabetes at Baseline Yes Yes Yes Diabetes Disease Duration (mean) < 10 yrs
Slide 18: Patients who used BT-001 more had greater reduction in A1c
Patients who used BT-001 more had greater reduction in A1c Participants self-selected dose of nCBT. Higher dose of nCBT lessons completed associated with larger A1c improvements at 180 days High Use of Low Use of Behavior Moderate Use of Behavior Therapy Therapy Behavior Therapy >20 lessons < 10 les
Slide 19: Higher dose subgroup shows greater A1c improvement compared to control
Higher dose subgroup shows substantially greater A1c improvement compared to Standard of Care control group Baseline A1c D90 A1c D180 A1c 0.2 0.1 SOC 0 -0.1 BT-001 -0.2 -0.3 Moderate use -0.4 (10-20 lessons) -0.5 High use -0.6 (>20 lessons) 19 % Mean Change in A1c
Slide 20: 1.5x more BT-001 patients achieved meaningful A1c change
1.5x more BT-001 patients achieved meaningful A1c change Significant improvements observed in BT-001 Group despite use of fewer diabetes medications ITT Population at D180 Δ = 16.1% p = 0.0004 Achieve 1% or more % 0 A1c reduction 30 (vs 17%, p=0.001) 10 20 30 34.3% 40 Achieve blood sugar % 50 contro
Slide 21: BT-001 Meaningful Responders show range of large improvements
BT-001 Meaningful Responders show range of large improvements at 180 days Meaningful Responders” defined as 0.4% or more A1c improvement MEAN -1.3% MEDIAN 14% -1.1% 12% 10% 8% 6% 4% 2% 0% -0.4 -0.5 -0.6 -0.7 -0.8 -0.9 -1 -1.1 -1.2 -1.3 -1.4 -1.5 -1.6 -1.7 -1.8 -1.9 -2 -2.1 -2.2 -2.3 -2.4 -2.5 -2.6 -
Slide 22: Safety data reveals significantly fewer Adverse Events
180 Day safety data reveals significantly fewer Adverse Events BT-001 patients had statistically significant fewer AEs and Serious AEs Standard of Care BT-001 (n=343) (n=325) Subjects Events Subjects Events Number of subjects who experienced: n (%) n n (%) n An Adverse Event (AE) 188 (54.8%) 324 135
Slide 23: BT-001 patients avoided more Serious Adverse Events
BT-001 patients avoided more Serious Adverse Events (SAEs) commonly found in T2 diabetes Standard of Care BT-001 (n=343) (n=325) Subjects Events Subjects Events Number of subjects who experienced: n (%) n n (%) n A Serious Adverse Event (SAE) 24 (7.0%) 26 9 (2.8%) 9 SAEs Possibly Related to Diabetes
Slide 24: More Adverse Events not observed with more use of BT-001
More Adverse Events (AEs and SAEs) are not observed with more use of BT-001 Participants self-selected dose. Higher dose associated with larger improvements, but not higher rates of AEs. Low Use of Moderate Use of High Use of Behavior Therapy Behavior Therapy Behavior Therapy < 10 lessons 10-20 less
Slide 25: Safety profiles of top performing diabetes drugs differ from BT-001
Safety profiles of top performing diabetes drugs differ from BT-001 Adverse Reaction (>/= 5%) GLP1 SGLT2 BT-001 Pivotal Nausea Yes No No Vomiting Yes No No Diarrhea Yes No No Abdominal pain Yes No No Constipation Yes No No Female genital mycotic infections No Yes No Urinary track infections No Yes N
Slide 26: Data reveals statistically significant changes in multiple exploratory endpoints
Statistically significant findings in: Data reveals • Systolic Blood Pressure statistically significant • Weight Reduction changes in multiple • Mood Scores exploratory endpoints, underscoring potential • Quality of Life Scores (Physical Health-Related) for broad-based • Adverse Event and Serious Ad
Slide 27: Medication and healthcare utilization increased more in control group
Antihyperglycemic medication utilization and healthcare utilization increased more in Standard of Care control group patients with a widening gap over 6- months 12.5% 10% BT-001 patients experienced fewer hospitalizations, ER 7.5% visits, and outpatient visits over length of study 5% 2.5% 0% Before
Slide 28: Patient engagement and persistence exceed benchmarks
During 180 days of use, patient engagement and persistence exceed benchmarks for consumer health & wellness apps* % 5.9 81 61 Average minutes / day Percentage of patients NPS Score after spent in app using the app at 180 days 180 days % % % % 36 38 36 35 Healthcare Health Medical Fitness (all) Insur
Slide 29: Marc Bonaca, MD, MPH
Marc Bonaca, MD, MPH Executive Director, CPC Clinical Research Associate Professor of Medicine, Cardiology, and Vascular Medicine Director of Vascular Research, University of Colorado School of Medicine 29
Slide 30: Qualities of an ideal new therapy in T2 Diabetes
Qualities of an ideal new therapy in T2 Diabetes 1 Non-pharmacologic Can be prescribed and data tracked in medical record 2 Ad Add dre ressi ssing ng the the unm unme et t ne nee ed ds s iin n Additive effects on top of evidence-based therapy 3 Ty Typ pe e 2 2 D Diia ab be ete tes s re req qui uire
Slide 31: Qualities of an ideal new therapy in T2 Diabetes
Qualities of an ideal new therapy in T2 Diabetes Non-pharmacologic Can be prescribed and data tracked in medical record Addressing the unmet needs in Additive effects on top of evidence-based therapy Type 2 Diabetes requires new Potential to decrease need for medication and/or therapies healthcare u
Slide 32: Go to market focus on patients with uncontrolled blood sugar
We intend to go to market with a focus on patients whose blood sugar remains uncontrolled despite the use of medications COST IN 2020* Adult US Population Diabetes 258M population ~$490B Adult US population with Type 2 Diabetes 34M Diagnosed Population COST IN 2030* 26M ~$600B Uncontrolled Type 2 13
Slide 33: BT-001 potential first-in-class Prescription Digital Therapeutic for Type 2 Diabetes
BT-001 has the potential to be the first-in-class Prescription Digital Therapeutic for the treatment of Type 2 Diabetes 33
Slide 34: Bipartisan Bill, CPT and HCPCS Codes
Bipartisan Bill Introduced: CPT Codes: March 10, 2022 Reps. Mike Thompson (CA-05) and David New for 2022/2023 CPT Editorial Panel accepted McKinley (WV-01) and Sens. Jeanne Shaheen (D-NH) and the use of temporary codes to identify supplying a Shelly Moore Capito (R-WV) introduced the bipartisan devi
Slide 35: Path to Regulatory Approval
PATH TO REGULATORY APPROVAL We plan to focus on securing coverage from regionally dominant, early adopting commercial payers, IDNs/health systems PAYERS HEALTH SYSTEMS • Centralized decision-making LEADING • Population health focused INDICATORS OF • Accountable Care • History of adopting new ADOPTIO
Slide 36: Real-world evidence program
Real-world evidence from randomized, controlled, multi-site program will inform our understanding of durability, impact on costs and medication use BT-001 Study Size Duration Participants Population: Participants with type 2 diabetes; A1c between 7.0% and 11.0%, not on prandial insulin 500 750 18-mo
Slide 37: Payer Survey
Payer Survey National and regional payers, as well as PBMs reacted positively to BT-001’s Target Product Profile Likelihood to Cover BT-001 (n=14) 71% responded “likely to cover” Source: Better Therapeutics Quantitative Market Research, June 2022. The 1 to 7 scale represents the likelihood of the 37
Slide 38: Provider Survey
Provider Survey Providers have expressed a willingness to prescribe BT-001 based on Target Product Profile Likelihood to Prescribe BT-001 (n=25) 88% rated “likely to prescribe” Source: Better Therapeutics Quantitative Market Research, Mar 2022. The 1 to 7 scale represents the likelihood of the 38 pr
Slide 39: Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases
Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases
Slide 40: Key Priorities and Upcoming Milestones
Key Priorities Upcoming Milestones Q3 2022 De Novo Submission Financing – initiated a broad assessment of potential financing options to support our commercial launch and Q3 2022 potentially expand into other cardiometabolic diseases. Health economic model for BT-001 and payer coverage discussions D
Slide 41: Q&A
JULY 28, 2022 BT-001 Pivotal Clinical Trial Results Q&A
Better Therapeutics — Technical Presentation (July 2022) on 6ix